Through the regulation of immune responses and reinforcement of antitumor effects, these interventions influence the levels of Th1, Th17, and Th2 cytokines, augmenting IL-2, tumor TNF-α, IFN-γ, and IL-17A, while diminishing IL-10 levels [32]. The gene discussed is IFNG; the disease is neoplasm.